News

Filter

Current filters:

None

Popular Filters

1 to 25 of 8860 results

USA’s 340B Drug Discount Program “needs more oversight,” says BIO

USA’s 340B Drug Discount Program “needs more oversight,” says BIO

01-08-2014

The US Biotechnology Industry Organization’s (BIO) Laurel Todd shared concerns that the 340B program…

BiotechnologyFinancialHealthcareRegulationUSA

Kyowa Hakko Kirin files for KW-3357 approval in Japan

Kyowa Hakko Kirin files for KW-3357 approval in Japan

01-08-2014

Japanese drugmaker Kyowa Hakko Kirin has filed an application for marketing approval with the Ministry…

HematologyJapanKW-3357Kyowa Hakko KirinPharmaceuticalRare diseasesRegulationThrombus

UCB expands access to clinical trial data

UCB expands access to clinical trial data

01-08-2014

Belgian drugmaker UCB is now part of the Multi-Sponsor Environment, allowing for the responsible sharing…

BelgiumClinical researchPharmaceuticalResearchUCB

FDA approves Boehringer’s Striverdi Respimat for COPD

FDA approves Boehringer’s Striverdi Respimat for COPD

01-08-2014

The US Food and Drug Administration has approved German family-owned pharma major Boehringer Ingelheim’s…

Boehringer IngelheimPharmaceuticalPulmonologyRegulationRespiratory and PulmonaryStriverdi RespimatUSA

Teva’s 2nd-qtr sales and earnings miss analysts' estimates

Teva’s 2nd-qtr sales and earnings miss analysts' estimates

31-07-2014

Israel’s Teva Pharmaceutical Industries, the world’s biggest generics drugmaker, reported disappointing…

CopaxoneFinancialGenericsIsraelTeva Pharmaceutical Industries

UCB reports solid 1st-half performance

UCB reports solid 1st-half performance

31-07-2014

Belgian drugmaker UCB posted first-half 2014 revenue of 1.76 billion euros ($2.36 billion), plus 6%,…

BelgiumChemistryChief executiveEURFinancialOrganic chemistryPharmaceuticalUCBVimpat

US seniors save more than $11.5 billion on Rx drugs since 2010

US seniors save more than $11.5 billion on Rx drugs since 2010

31-07-2014

Information released by the US Department of Health and Human Services shows that more than 8.2 million…

FinancialHealthcareMedicarePharmaceuticalUSA

Harlan aims to provide expertise for biologics and biosimilars

31-07-2014

Switzerland-based Harlan Laboratories, a privately held provider of general and specialty toxicology…

BiosimilarsBiotechnologyContract research servicesHarlanRegulationResearchSwitzerlandToxicology services

Janssen’s simeprevir for hepatitis C shows good efficacy in Phase II trial

Janssen’s simeprevir for hepatitis C shows good efficacy in Phase II trial

31-07-2014

Some 92% of genotype 1 chronic hepatitis C virus (HCV) adult patients treated with US health care giant…

Anti-viralsGilead SciencesIrelandJanssenPharmaceuticalResearchsimeprevirsofosbuvir

Valeant's revenue jumps 86% to hit $2 billion

Valeant's revenue jumps 86% to hit $2 billion

31-07-2014

Canadian pharma company Valeant, which is currently attempting a takeover of Allergan, reported a 12-fold…

AllerganBausch & LombCanadaFinancialPharmaceuticalValeantValeant Pharmaceuticals

Albumin sales to play major part in growth of billion-dollar critical care market

Albumin sales to play major part in growth of billion-dollar critical care market

31-07-2014

The critical care market across eight major countries will grow to $2.5 billion by 2020, according to…

AlbuminBlood proteinsGlobalMarkets & MarketingPharmaceutical

AstraZeneca 2nd-qtr earnings leap, beating expectations

AstraZeneca 2nd-qtr earnings leap, beating expectations

31-07-2014

Anglo-Swedish pharma major AstraZeneca, which earlier this year defended itself against an unsolicited…

AstraZenecaBusiness FinanceFinancialPharmaceuticalUK

Meda in $3.1 billion deal to acquire Italy’s Rottapharm

Meda in $3.1 billion deal to acquire Italy’s Rottapharm

31-07-2014

Sweden’s Meda says it has entered into a definitive agreement to acquire Rottapharm Madaus, an Italian…

Business FinanceItalyMedaMergers & AcquisitionsMergers and acquisitionsPharmaceuticalRottapharm MadausSwedenSweden

Novartis' KAE609 effective in uncomplicated malaria patients

Novartis' KAE609 effective in uncomplicated malaria patients

31-07-2014

Swiss drug major Novartis says that results published in the New England Journal of Medicine show that…

Antibiotics and Infectious diseasesJoseph JimenezKAE609NovartisPharmaceuticalPlasmodiumResearchSwitzerland

NICE consulting again on Celgene's Revlimid for multiple myeloma

NICE consulting again on Celgene's Revlimid for multiple myeloma

31-07-2014

The UK clinical guidance body, the National Institute for Health and Care Excellence (NICE), is again…

Celgene Corp.ImmunosuppressantslenalidomideOncologyPharmaceuticalRegulationRevlimidUK

Sanofi posts strong 2nd-qtr earnings, beating estimates

Sanofi posts strong 2nd-qtr earnings, beating estimates

31-07-2014

French pharma major Sanofi this morning reported that group sales for the second quarter of 2014 grew…

FinancialFranceGaucherGenzymeInsulin glargineMajorMiddle EastPharmaceuticalSanofi

Pfizer spends $635 million on acquiring two Baxter vaccines

Pfizer spends $635 million on acquiring two Baxter vaccines

30-07-2014

US pharma giant Pfizer has entered into a definitive agreement to acquire Baxter International portfolio…

Baxter InternationalMergers & AcquisitionsPfizerPharmaceuticalProductionUSAVaccines

Regeneron’s Eylea gains FDA approval for DME

Regeneron’s Eylea gains FDA approval for DME

30-07-2014

The Food and Drug Administration has approved US biotech firm Regeneron Pharmaceuticals’ Eylea (aflibercept)…

BayerBiotechnologyEyleaOphthalmicsRegeneronRegulationUSA

1 to 25 of 8860 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top